Luminor Medical Announces Change in Auditor

MONTREAL, QC / ACCESSWIRE / March 17, 2017 / Luminor Medical Technologies Inc. (TSX-V: LMT) (OTC PINK: MCUID / MCUIF) (the “Company” or “Luminor Medical”) (formerly Miraculins Inc.) announces that it has changed its auditors from KPMG LLP. (the “Former Auditors”) to MNP LLP. (the “Successor Auditors”), effective March 10, 2017.

At the request of the Company, the Former Auditors resigned as auditors of the Company effective March 10, 2017, and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective March 10, 2017, until the next Annual General Meeting of the Company.

There were no reservations in the Former Auditor’s reports in connection with the most recently completed fiscal year (2015) or for any period subsequent to the most recently completed period for which an audit report was issued preceding the date of the Former Auditor’s resignation. There are no “reportable events” (as that term is defined in National Instrument 51-102 Continuous Disclosure Obligations) between the Company and the Former Auditor.

In accordance with National Instrument 51-102, the notice of change of auditor, together with the required letters from the former auditor and the successor auditor, have been reviewed by the audit committee and the board of directors and has been filed on SEDAR.

About Luminor Medical Technologies

Luminor Medical Technologies is a medical diagnostic company focused on acquiring, developing, and commercializing non-invasive technologies for unmet clinical needs. The Company’s Scout DS® device has been regulatory cleared in certain markets, both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and as the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world.

For more information, please contact:

Christian Sauvageau
President & CEO
Luminor Medical Technologies Inc.
Ph: (438) 889-3585

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Luminor Medical Technologies Inc.

ReleaseID: 457626